| Literature DB >> 24612913 |
María Teresa Solis Soto1, Armando Patiño, Dennis Nowak, Katja Radon.
Abstract
BACKGROUND: Asthma and allergies are world-wide common chronic diseases among children and young people. Little information is available about the prevalence of these diseases in rural areas of Latin America. This study assesses the prevalence of symptoms of asthma and allergies among children in urban and rural areas at Oropeza Province in Bolivia.Entities:
Mesh:
Year: 2014 PMID: 24612913 PMCID: PMC3975636 DOI: 10.1186/1471-2466-14-40
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Descriptive data by for place of living (N = 2340)
| | | |||||
|---|---|---|---|---|---|---|
| Female | 917 | 53.2 | 300 | 48.9 | 0.14 | |
| ≤ 10 years | 822 | 48.0 | 175 | 28.6 | < 0.01 | |
| 11 years | 672 | 39.3 | 303 | 49.4 | ||
| ≥ 12 years | 218 | 12.7 | 135 | 22.0 | ||
| Public | 1400 | 81.1 | 351 | 57.3 | 0.17 | |
| Private and public with private Infrastructure | 327 | 18.9 | 262 | 42.7 | ||
*Chi square test.
Prevalence, unadjusted and adjusted odds ratios comparing self-reported asthma, rhinitis and eczema in school aged children from rural and urban areas
| | ||||||
|---|---|---|---|---|---|---|
| Written questionnaire (N = 2340) | ||||||
| Wheeze (ever) | 470 | 27.4 | 214 | 34.9 | 0.7 (0.4-1.9) | 0.7 (0.4-1.9) |
| Wheeze (12 months prevalence) | 281 | 16.4 | 133 | 21.7 | 0.6 (0.4-1.9) | 0.6 (0.4-1.9) |
| Severe asthmaa (12 months prevalence) | 158 | 9.2 | 76 | 12.4 | 0.7 (0.4-1.9) | 0.7 (0.5-1.9) |
| Video questionnaire (N = 2300) | ||||||
| Wheezing (12 months prevalence) | 124 | 7.3 | 24 | 3.9 | 2.3 (1.1-2.7) | 2.1 (1.0-2.6) |
| Exercise-induced wheeze (12 months prevalence) | 323 | 19.2 | 80 | 13.1 | 1.7 (0.9-2.4) | 1.7 (0.9-2.4) |
| Dyspnoea at rest (12 months prevalence) | 68 | 4 | 17 | 2.8 | 1.8 (0.7-3.1) | 1.7 (0.7-3.2) |
| Rhinitis (ever) | 715 | 41.7 | 255 | 41.6 | 1.0 (0.7-1.6) | 1.0 (0.7-1.6) |
| Rhinitis (12 months prevalence) | 490 | 28.6 | 175 | 28.5 | 1.0 (0.7-1.6) | 1.0 (0.8-1.6) |
| Rhinoconjunctivitisd (12 months prevalence) | 369 | 21.5 | 147 | 24.0 | 0.8 (0.6-1.8) | 0.8 (0.6-1.8) |
| Severe Rhinoconjunctivitise (12 months prevalence) | 43 | 2.5 | 6 | 1.0 | 2.6 (1.1-7.8) | 2.8 (1.2-6.6) |
| Itchy rash (ever) | 339 | 20 | 123 | 20.1 | 1.0 (0.7-1.7) | 1.0 (0.7-1.7) |
| Itchy rash (12 months prevalence) | 203 | 12.0 | 56 | 9.2 | 1.4 (0.9-1.8) | 1.4 (1.0-1.8) |
| Eczemaf (12 months prevalence) | 161 | 9.5 | 52 | 8.5 | 1.1 (0.7-1.8) | 1.2 (0.8-1.8) |
| Severe Eczemag (12 months prevalence) | 27 | 1.6 | 3 | 0.5 | 3.3 (1.0-10.9) | 3.3 (1.0-11.0) |
a ≥ 4 attacks of wheeze or woken by wheeze on one or more nights per week or wheezing severe enough to limit speech to only one or two words at a time, between breaths.
bReference category: rural.
cAdjusted by age.
dPresence of sneezing or a runny or blocked nose, accompanied by itchy watery eyes without a cold or the flu.
eRhinoconjunctivitis symptoms interfering with daily activities (a lot).
fPresence of an itchy rash at any time in the past 12 months affecting the following places: the folds of the elbows; behind the knees; in front of the ankles; under the buttocks; or around the neck, ears, or eyes).
gSleep disturbed by rash in the last 12 months in children with eczema symptoms (one or more nights per week).